World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
111
Citations
63499
World Ranking
5242
National Ranking
56

Marc Buyse publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc Buyse sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 562 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Marc Buyse D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Buyse sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Marc Buyse is affiliated with Hasselt University in Belgium and has contributed extensively to the field of medicine, with a particular focus on oncology and statistical methods applied to clinical trials. Their research portfolio spans multiple dimensions of cancer research, health systems, and economic evaluations in medical treatments.

The main fields of study associated with their work include:

  • Medicine

Subfields with significant representation in their publications are:

  • Oncology
  • Statistics and Probability
  • Pulmonary and Respiratory Medicine
  • Economics and Econometrics
  • Cancer Research

The primary topics researched by Marc Buyse encompass:

  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Colorectal Cancer Treatments and Studies
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Surgical Treatments
  • Prostate Cancer Treatment and Research
  • Advanced Causal Inference Techniques

Notable recent papers authored or co-authored by Marc Buyse include:

  • International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer, 2021, Nature Reviews Clinical Oncology
  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, 2023, Journal of Clinical Oncology
  • Outcome measures in multimodal rectal cancer trials, 2020, The Lancet Oncology
  • Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer, 2023, Journal of Clinical Oncology
  • Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy, 2022, The Oncologist

Frequent co-authors collaborating with Marc Buyse include:

  • Everardo D. Saad
  • Tomasz Burzykowski
  • Susan Halabi
  • Nicholas D. James
  • Mickaël De Backer

The scientist has published extensively in several key journals, notably:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • JAMA Oncology
  • Therapeutic Innovation & Regulatory Science
  • Biometrical Journal

Best Publications

  • FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

    Christophe Tournigand;Thierry André;Emmanuel Achille;Gérard Lledo

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

    Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris

  • Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate by the advanced colorectal cancer meta-analysis project

    P. Piedbois;M. Buyse;Y. Rustum;D. Machover

  • Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

    Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale

  • Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

    P Piedbois;P Rougier;M Buyse

  • Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

    Ugo Pastorino;Marc Buyse;Godehard Friedel;Robert J. Ginsberg

  • Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group.

    IC Henderson;H Mouridsen;O Abe;M Abeloff

  • Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials

    R. Gray;Robert Kerrin Hills;R. Stowe;M. Clarke

  • Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,

    Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang

  • OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

    Christophe Tournigand;Andres Cervantes;Arie Figer;Gérard Lledo

  • Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

    Mitch Dowsett;Jack Cuzick;Jim Ingle;Alan Coates

  • Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade

    Sherene Loi;Benjamin Haibe-Kains;Christine Desmedt;Françoise Lallemand

  • Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

    Christine Desmedt;Benjamin Haibe-Kains;Pratyaksha Wirapati;Marc Buyse

  • THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER. GYNECOLOGICAL CANCER COOPERATIVE GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER

    Maria E.L. van der Burg;Mat van Lent;Marc Buyse;Anna Kobierska

  • Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis

    Gastric (Global Advanced);Xavier Paoletti;Koji Oba

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC).

    André Gerard;Marc Buyse;Bernard Nordlinger;Jean Loygue

  • Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials

    J. Bergh;K. Pritchard;K. Albain;S. Anderson

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

    Daniel J. Sargent;Harry S. Wieand;Daniel G. Haller;Richard Gray

Frequent Co-Authors

Christos Sotiriou
Christos Sotiriou Université Libre de Bruxelles
Stefan Michiels
Stefan Michiels University of Paris-Saclay
Benjamin Haibe-Kains
Benjamin Haibe-Kains Princess Margaret Cancer Centre
Denis Larsimont
Denis Larsimont Université Libre de Bruxelles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Mauro Delorenzi
Mauro Delorenzi University of Lausanne
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degree options is a smart way to broaden your career pathways in the medical field. If you are aiming for advanced practice, accredited online dnp programs offer rigorous, flexible training for nurses seeking leadership or specialized roles. Some candidates may prefer dnp programs without dissertation, which can streamline the academic process and better accommodate working professionals.

For those looking to enter the healthcare workforce faster, a 9 month lpn program offers an accelerated route into practical nursing positions. Rapid entry into roles like Licensed Practical Nurse provides direct patient care experience, which is valuable for those considering future medical study.

Mental health is another growing focus in medicine. Nurses can quickly upskill in this specialty through fast track mental health nursing programs online, helping to address urgent mental health care needs across the country.

Each of these pathways supports flexible study, making it easier to balance your career goals with current commitments.

Best Scientists Citing Marc Buyse

Trending Scientists

Recently Published Articles